International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 182-184
PROGRESS IN TARGETED AND THE ADJUVANT TREATMENT OF LUNG CANCER AND ONGOING STUDIES
ÖZDEN ALTUNDAĞ1, KADRİ ALTUNDAĞ1
The University of Texas, M.D. Anderson Cancer Center, Medical Oncology, Houston, Texas, USA
Recently significant progress has been achieved in targeted and the adjuvant treatment of lung cancer. Especially, two important randomized trials presented in ASCO 2004 meeting have resolved one of oncology's long-standing debates. Adjuvant therapy in early-stage, non-small-cell lung cancer does improves survival. Meanwhile, clinical treatment of non-small cell lung cancer with agents named as targeted therapy designed to either antagonize, activate the activity of specific cellular factors has finally become a reality. Although these agents are far from curative, wide use is expected, especially because of their limited toxicity. We summarize recently presented data and ongoing studies in the field.
ÖZDEN ALTUNDAĞ1, KADRİ ALTUNDAĞ1
The University of Texas, M.D. Anderson Cancer Center, Medical Oncology, Houston, Texas, USA
Recently significant progress has been achieved in targeted and the adjuvant treatment of lung cancer. Especially, two important randomized trials presented in ASCO 2004 meeting have resolved one of oncology's long-standing debates. Adjuvant therapy in early-stage, non-small-cell lung cancer does improves survival. Meanwhile, clinical treatment of non-small cell lung cancer with agents named as targeted therapy designed to either antagonize, activate the activity of specific cellular factors has finally become a reality. Although these agents are far from curative, wide use is expected, especially because of their limited toxicity. We summarize recently presented data and ongoing studies in the field.